Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/313343 
Erscheinungsjahr: 
2022
Quellenangabe: 
[Journal:] The European Journal of Health Economics [ISSN:] 1618-7601 [Volume:] 23 [Issue:] 8 [Publisher:] Springer [Place:] Berlin, Heidelberg [Year:] 2022 [Pages:] 1287-1296
Verlag: 
Springer, Berlin, Heidelberg
Zusammenfassung: 
Objective: Scholars previously estimated research and development (R&D) costs of the internal drug development process. However, little is known about the costs and value arising from externally acquired therapeutics. This study identifies and estimates the magnitude of factors associated with Biopharma acquisition value. Methods: SDC Thomson Reuter and S&P Capital IQ were screened for majority acquisitions of US and EU Biopharma companies developing new molecular entities for prescription use (SIC code: 2834) from 2005 to 2020. Financial acquisition data were complemented with variables characterizing the target’s product portfolio extracted from clinicaltrials.gov, Drugs
Zusammenfassung (übersetzt): 
FDA database, US SEC filings, and transaction announcements. A multivariate regression assesses the association of firm value with extracted variables. Results: 311 acquisitions of companies developing prescription drugs were identified over the study period. Acquirers paid 37% ( p  < 0.05) more for companies with biologics and gene therapeutics than small-molecule lead drugs. Multi-indication products were acquired for a 12% premium per additional indication ( p  < 0.01). No significant valuation difference between companies developing orphan and non-orphan designated lead products was observed (18%, p  = 0.223). Acquisition value positively correlated with the total number of further products, headquarter location in the US, underlying market conditions, and acquirer market capitalization ( p  < 0.05). Conclusions: Internal and external drug development consumes many financial and human resources, yet it is important for entrepreneurs, regulators, and payers to understand their precise magnitude and value drivers. This information permits the design of targeted pricing and industrial policies that incentivize the development of novel drugs in areas with high unmet needs.
Schlagwörter: 
Multi-indication
Pharmaceutical policy
Orphan
Valuation
Acquisitions
Drug development
Persistent Identifier der Erstveröffentlichung: 
Creative-Commons-Lizenz: 
cc-by Logo
Dokumentart: 
Article
Dokumentversion: 
Published Version

Datei(en):
Datei
Größe





Publikationen in EconStor sind urheberrechtlich geschützt.